Compare Dropbox Inc (DBX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Merck & Co., Inc. — how do they compare? Dropbox Inc trades at $30.33 (market cap $6.99B), while Merck & Co., Inc. trades at $124.1 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 42.7× Dropbox Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Dropbox Inc pays none. Which is the better fit depends on your goals.
| DBX | MRK | |
|---|---|---|
Market Cap | $6.99B | $298.31B |
Sector | Technology | Health |
52-Week High | $32.17 | $129.52 |
52-Week Low | $22.06 | $77.60 |
Enterprise Value | $9.71B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $29.58, up 1.34% on the day, near the analyst consensus price target of $30. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate potential overbought conditions. Fundamentally, the company maintains robust profitability with a net income margin of 18.71% and has beaten earnings estimates for three consecutive quarters. Recent news highlights a new $900 million stock repurchase program and a CEO transition plan announced in May 2026.
The outlook is balanced with solid fundamentals and shareholder returns offset by high debt levels and mixed analyst sentiment. Investment appeal lies in consistent earnings beats and capital return initiatives, but risks include elevated leverage and competitive pressures in cloud storage. The stock presents a moderate opportunity with cautious optimism warranted given its valuation near target prices.
Merck (MRK) trades at $120.8, down 2.6% on the day, with a bullish technical signal and strong support near $120. Recent earnings have consistently beaten expectations, including Q1 2026's smaller-than-expected loss. The company is acquiring Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Revenue reached $65.01B in 2025 with a net income margin of 28.07%, though 2026 projections show a decline to 13.58%.
The outlook remains positive with a consensus price target of $137.30, implying 13.7% upside. Key opportunities include pipeline expansion via M&A and robust profitability, but risks involve rising debt, patent expirations, and competitive pressures. Institutional buying activity supports bullish sentiment, though earnings volatility and macroeconomic factors warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
